Match!
Fernando Gomez-Peralta
EndocrinologyType 2 diabetesHypoglycemiaDiabetes mellitusMedicine
34Publications
8H-index
185Citations
What is this?
Publications 37
Newest
Insulclock is an electronic device designed to improve treatment adherence and insulin injection tracking. This randomized, single-center, pilot study assessed the clinical impact of Insulclock on ...
Source
Objective Observations in real-world settings support and extend findings demonstrated in randomized controlled trials that show flash glucose monitoring improves glycemic control. In this study, Spain-specific relationships between testing frequency and glycemic parameters were investigated under real-world settings. Research design and methods Deidentified glucose and user scanning data were analyzed and readers were rank ordered into 20 equal sized groups by daily scan frequency. Glucose para...
Source
#1Ana Chico (Autonomous University of Barcelona)H-Index: 13
Last. Cintia González-Blanco (Autonomous University of Barcelona)
view all 17 authors...
The flash glucose monitoring (FGM) system FreeStyle Libre® is a device that measures interstitial glucose in a very simple way and indicates direction and speed of glucose change. This allows perso...
Source
#1Carlos MorillasH-Index: 13
#2Javier Escalada (University of Navarra)H-Index: 6
Last. Antonio PérezH-Index: 26
view all 6 authors...
Introduction The aim of this Delphi study is to unveil the management of patients with type 2 diabetes (T2D) and different levels of complexity in the clinical practice in Spain.
Source
#2Itziar OyagüezH-Index: 8
Last. Miguel Ángel CasadoH-Index: 13
view all 8 authors...
FreeStyle Libre system is a sensor-based flash monitoring (FM) system, which assesses interstitial fluid glucose. The study aimed to estimate the cost associated with FM compared to self-monitoring of blood glucose (SMBG) in a type 1 diabetes mellitus (T1DM) adult population from the Spanish National Health System perspective The annual cost was modeled for glucose monitoring in T1DM with multiple daily insulin (MDI) doses in a vulnerable subgroup, such as disabled patients (blind, Down’s syndro...
Source
Abstract Background: Achieving and maintaining controlled glycemic levels are challenging in people with insulin-treated diabetes mellitus, suboptimal insulin injections being the main obstacle to ...
Source
2 CitationsSource
#1Irene Romera (Eli Lilly and Company)H-Index: 10
Last. Jesús Reviriego (Eli Lilly and Company)H-Index: 9
view all 5 authors...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are well established as effective treatments for patients with type 2 diabetes. GLP-1 RAs augment insulin secretion and suppress glucagon release via the stimulation of GLP-1 receptors. Although all GLP-1 RAs share the same underlying mechanism of action, they differ in terms of formulations, administration, injection devices and dosages. With six GLP-1 RAs currently available in Europe (namely, immediate-release exenatide, lixisenatide, lira...
3 CitationsSource
Abstract Type 2 diabetes mellitus (DM2) has become a problem of global dimensions by their high and growing prevalence worldwide and the personal and economic costs associated with it. Correct treatment can reduce mortality and associated complications. New concepts have recently been included in routine clinical practice and have changed the algorithm of DM2 pharmacological therapy. Therefore, the Spanish Society of Diabetes (SED) entrusted to the Working Group of Consensus and Clinical Guideli...
1 CitationsSource
Resumen La diabetes mellitus tipo 2 (DM2) es un problema de dimensiones globales por su alta y creciente prevalencia en todo el mundo y por los costes personales y economicos asociados a ella. Un tratamiento adecuado ha demostrado reducir la mortalidad y las complicaciones asociadas. Recientemente se han incluido nuevos conceptos en la practica clinica habitual y en el arbol de decision de la terapia farmacologica de la DM2. Por ello, la Sociedad Espanola de Diabetes (SED) encargo al Grupo de Tr...
2 CitationsSource
1234